Pfizer: Poised For Gains With A New Drug Pipeline And Cost-Cutting Plans

Pfizer: Poised For Gains With A New Drug Pipeline And Cost-Cutting Plans

Pfizer Inc. faces a significant loss of exclusivity wall, but the biopharma has a new drug pipeline and cost-cutting plans to cover most of the sales hits. PFE guided 2026 revenues to $61.5B, with COVID-19 revenues now minimal and high single-digit growth projected starting in 2029. The company has another major cost reduction plan for savings of up to $4B to offset most gross profit losses from LoEs, supporting stable EPS near $2.90 through 2028. Patient investors benefit from a 6.2% dividend yield as PFE transitions, with upside potential from acquired franchises like Metsera, Seagen, and Biohaven.

Pfizer Inc. ( PFE ) has still struggled to move beyond the COVID-19 boosts. The large biopharma remains a cash flow machine rewarding investors with large capital returns, but Pfizer lacks growth through the end of the This article was written by Stone Fox Capital 56.68K Followers Follow Stone Fox Capital is an RIA from Oklahoma. Mark Holder is a CPA with degrees in Accounting and Finance. He is also Series 65 licensed and has 30 years of investing experience, including 15 years as a portfolio manager. Mark leads the investing group Out Fox The Street where he shares stock picks and deep research to help readers uncover potential multibaggers while managing portfolio risk via diversification. Features include various model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and access to community chat and direct chat with Mark for questions. Learn more.